We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ANI Pharmaceuticals is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 5.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ANIP has returned about 45.4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 6.4% on a year-to-date basis. As we can see, ANI Pharmaceuticals is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Aveanna Healthcare (AVAH - Free Report) . The stock has returned 97.4% year-to-date.
The consensus estimate for Aveanna Healthcare's current year EPS has increased 40.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 465 individual companies and currently sits at #87 in the Zacks Industry Rank. On average, this group has gained an average of 18.4% so far this year, meaning that ANIP is performing better in terms of year-to-date returns.
On the other hand, Aveanna Healthcare belongs to the Medical - Outpatient and Home Healthcare industry. This 15-stock industry is currently ranked #32. The industry has moved +8.3% year to date.
Investors with an interest in Medical stocks should continue to track ANI Pharmaceuticals and Aveanna Healthcare. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ANI Pharmaceuticals is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANIP's full-year earnings has moved 5.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ANIP has returned about 45.4% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 6.4% on a year-to-date basis. As we can see, ANI Pharmaceuticals is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Aveanna Healthcare (AVAH - Free Report) . The stock has returned 97.4% year-to-date.
The consensus estimate for Aveanna Healthcare's current year EPS has increased 40.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 465 individual companies and currently sits at #87 in the Zacks Industry Rank. On average, this group has gained an average of 18.4% so far this year, meaning that ANIP is performing better in terms of year-to-date returns.
On the other hand, Aveanna Healthcare belongs to the Medical - Outpatient and Home Healthcare industry. This 15-stock industry is currently ranked #32. The industry has moved +8.3% year to date.
Investors with an interest in Medical stocks should continue to track ANI Pharmaceuticals and Aveanna Healthcare. These stocks will be looking to continue their solid performance.